Merck & Co. Pounces On Moderna mRNA-Based Cancer Vaccine Option
The company will pay Moderna $250m upfront to develop and commercialize a personalized cancer vaccine for melanoma in combination with Keytruda.
You may also be interested in...
The company aims to deliver DNA via lipid nanoparticles as well as delivering LNPs systemically to tissues beyond the liver and spleen, which the CEO called a “frontier” in an interview.
Phase IIb KEYNOTE-942 study shows mRNA-4157/V940 paired with Keytruda reduces risk of recurrence and death in post-surgical melanoma patients compared with Keytruda alone.
Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.